On this page, we highlight information of partcular relevance for media, including news, events and featured information for journalists with a professional interest in the development and availability of medicines in the European Union. For more information and details relevant for media, see our News & events section. For enquiries from media, please contact the EMA press office.
EMA 2018 annual report
EMA has published its 2018 annual report, which provides an overview of the work of the Agency together with the European medicines regulatory network. It highlights last year’s major achievements in protecting and promoting public and animal health in the European Union and contains key figures on the Agency’s regulatory procedures and activities.
News and press releases
Search and filter our news and press releases.
Find out more about EMA's scientific committees and working parties
Read more about the work of EMA's committees and working parties and find information on their meeting, including agendas and outcomes.
Funding, statistics and key operating information
You can find out more on how we work including statistics and information on financial management.
News for media
EMA celebrates 25 years advancing public and animal health
This week marks EMA’s 25th anniversary. Since the Agency’s creation on 26 January 1995, the environment in which EMA operates has undergone fundamental scientific, technological, legislative and social changes. But its mission has remained: bringing...
Martina Schüssler-Lenz re-elected as chair of Committee for Advanced Therapies
At its January meeting, EMA’s Committee for Advanced Therapies (CAT) re-elected Dr Martina Schüssler-Lenz as its chair, for a second three-year mandate. Dr Martina Schüssler-Lenz is the Deputy Head of the Advanced Therapy Medicinal Products Section...
Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 21-23 January 2020
First meeting of CVMP at the permanent office of EMA in Amsterdam CVMP opinions on veterinary medicinal products The Committee adopted by consensus a positive opinion for a type II variation application for Innovax-ND-IBD to add a new indication for...
Court of Justice upholds EMA’s approach to transparency
EMA welcomes today’s two appellate judgments by the Court of Justice 1 that confirmed, in clear and unambiguous terms, the right of citizens for access to clinical study and toxicology reports submitted to EMA for the purpose of the granting of a...
Ten recommendations to unlock the potential of big data for public health in the EU
The joint Big Data Task Force of EMA and the Heads of Medicines Agencies (HMA) proposes ten priority actions for the European medicines regulatory network to evolve its approach to data use and evidence generation, in order to make best use of big...
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 January 2020
EMA suspends Picato as a precaution while review of skin cancer risk continues At its January meeting, EMA’s safety committee (PRAC) recommended that patients stop using Picato (ingenol mebutate), a gel for treating the skin condition actinic...
Events of interest
List itemMon-Thu 13-16 Dec13/12/2021 - 16/12/2021
Committee for Medicinal Products for Human Use (CHMP): 13-16 December 2021
The Committee for Medicinal Products for Human Use (CHMP) is the committee that is responsible for...
List itemTue-Thu 07-09 Dec07/12/2021 - 09/12/2021
Committee for Medicinal Products for Veterinary Use (CVMP): 07-09 December 2021
The Committee for Medicinal Products for Veterinary Use (CVMP) is the committee that is responsible...
List itemMon-Thu 29-02 Nov-Dec29/11/2021 - 02/12/2021
Pharmacovigilance Risk Assessment Committee (PRAC): 29 November-2 December 2021
The Pharmacovigilance Risk Assessment Committee (PRAC) is the committee that is responsible for...
List itemMon-Wed 22-24 Nov22/11/2021 - 24/11/2021
Committee for Herbal Medicinal Products (HMPC): 22-24 November 2021
The Committee on Herbal Medicinal Products (HMPC) is the committee that is responsible for...